Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals

Molecular Therapy

Volumn 23, Issue 9, 2015, Pages 1456-1464

  Thess, Andreas ^a   Grund, Stefanie ^a   Mui, Barbara L ^b   Hope, Michael J ^b   Baumhof, Patrick ^a   Fotin Mleczek, Mariola ^a   Schlake, Thomas ^a  

^a CureVac GmbH   (Germany)

^b Acuitas Therapeutics   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; LIPID NANOPARTICLE; MESSENGER RNA; NANOPARTICLE; NUCLEOSIDE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BODY WEIGHT; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOKINE RELEASE; ERYTHROPOIESIS; EXPERIMENTAL ANIMAL; FEMALE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MOLECULAR THERAPY; MOUSE; NONHUMAN; PIG; PRIMATE; PROTEIN EXPRESSION; RETICULOCYTE COUNT; RNA SEQUENCE; SINGLE DRUG DOSE; ANIMAL; ANIMAL MODEL; BLOOD; CELL LINE; CHEMISTRY; GENE EXPRESSION; GENE THERAPY; GENETICS; MACACA FASCICULARIS; MEAN CORPUSCULAR VOLUME; METABOLISM; PROCEDURES; REPORTER GENE; SILENT MUTATION;

ANIMALS; CELL LINE; ERYTHROCYTE INDICES; ERYTHROPOIETIN; GENE EXPRESSION; GENES, REPORTER; GENETIC THERAPY; HUMANS; LIPIDS; MACACA FASCICULARIS; MICE; MODELS, ANIMAL; NANOPARTICLES; RNA, MESSENGER; SILENT MUTATION; SUS SCROFA;

EID: 84940720241     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.103     Document Type: Article

References (45)

1. Gurdon, JB, Lane, CD, Woodland, HR and Marbaix, G (1971). Use of frog eggs and oocytes for the study of messenger RNA and its translation in living cells. Nature 233: 177-182.
2. Laskey, RA, Gurdon, JB and Crawford, LV (1972). Translation of encephalomyocarditis viral RNA in oocytes of Xenopus laevis. Proc Natl Acad Sci USA 69: 3665-3669.
3. Boczkowski, D, Nair, SK, Snyder, D and Gilboa, E (1996). Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184: 465-472.
4. Wolff, JA, Malone, RW, Williams, P, Chong, W, Acsadi, G, Jani, A et al. (1990). Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1): 1465-1468.
5. Conry, RM, LoBuglio, AF, Wright, M, Sumerel, L, Pike, MJ, Johanning, F et al. (1995). Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 55: 1397-1400.
6. Jirikowski, GF, Sanna, PP, Maciejewski-Lenoir, D and Bloom, FE (1992). Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science 255: 996-998.
7. Alexopoulou, L, Holt, AC, Medzhitov, R and Flavell, RA (2001). Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738.
8. Diebold, SS, Kaisho, T, Hemmi, H, Akira, S and Reis e Sousa, C (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531.
9. Heil, F, Hemmi, H, Hochrein, H, Ampenberger, F, Kirschning, C, Akira, S et al. (2004). Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526-1529.
10. Hornung, V, Ellegast, J, Kim, S, Brzozka, K, Jung, A, Kato, H et al. (2006). 5'-Triphosphate RNA is the ligand for RIG-I. Science 314: 994-997.
11. Kato, H, Takeuchi, O, Sato, S, Yoneyama, M, Yamamoto, M, Matsui, K et al. (2006). Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101-105.
12. Pichlmair, A, Schulz, O, Tan, CP, Naslund, TI, Liljestrom, P, Weber, F et al. (2006). RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 314: 997-1001.
13. Rehwinkel, J, Tan, CP, Goubau, D, Schulz, O, Pichlmair, A, Bier, K et al. (2010). RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 140: 397-408.
14. Nallagatla, SR, Hwang, J, Toroney, R, Zheng, X, Cameron, CE and Bevilacqua, PC (2007). 5'-triphosphate-dependent activation of PKR by RNAs with short stem-loops. Science 318: 1455-1458.
15. Rittig, SM, Haentschel, M, Weimer, KJ, Heine, A, Muller, MR, Brugger, W et al. (2011). Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 19: 990-999.
16. Scheel, B, Aulwurm, S, Probst, J, Stitz, L, Hoerr, I, Rammensee, HG et al. (2006). Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol 36: 2807-2816.
17. Weide, B, Carralot, JP, Reese, A, Scheel, B, Eigentler, TK, Hoerr, I et al. (2008). Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 31: 180-188.
18. Weide, B, Pascolo, S, Scheel, B, Derhovanessian, E, Pflugfelder, A, Eigentler, TK et al. (2009). Direct injection of protamine-protected mRNA: results of a phase . vaccination trial in metastatic melanoma patients. J Immunother 32: 498-507.
19. Fotin-Mleczek, M, Duchardt, KM, Lorenz, C, Pfeiffer, R, Ojki?-Zrna, S, Probst, J et al. (2011). Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34: 1-15.
20. Kariko, K, Buckstein, M, Ni, H and Weissman, D (2005). Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23: 165-175.
21. Anderson, BR, Muramatsu, H, Jha, BK, Silverman, RH, Weissman, D and Kariko, K (2011). Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res 39: 9329-9338.
22. Anderson, BR, Muramatsu, H, Nallagatla, SR, Bevilacqua, PC, Sansing, LH, Weissman, D et al. (2010). Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res 38: 5884-5892.
23. Kariko, K, Muramatsu, H, Welsh, FA, Ludwig, J, Kato, H, Akira, S et al. (2008). Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16: 1833-1840.
24. Warren, L, Manos, PD, Ahfeldt, T, Loh, YH, Li, H, Lau, F et al. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7: 618-630.
25. Zangi, L, Lui, KO, von Gise, A, Ma, Q, Ebina, W, Ptaszek, LM et al. (2013). Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol 31: 898-907.
26. Kormann, MS, Hasenpusch, G, Aneja, MK, Nica, G, Flemmer, AW, Herber-Jonat, S et al. (2011). Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 29: 154-157.
27. Kariko, K, Muramatsu, H, Keller, JM and Weissman, D (2012). Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther 20: 948-953.
28. Jayaraman, M, Ansell, SM, Mui, BL, Tam, YK, Chen, J, Du, X et al. (2012). Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 51: 8529-8533.
29. Martinon, F, Krishnan, S, Lenzen, G, Magne, R, Gomard, E, Guillet, JG et al. (1993). Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 23: 1719-1722.
30. Hoerr, I, Obst, R, Rammensee, HG and Jung, G (2000). In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30: 1-7.
31. Petsch, B, Schnee, M, Vogel, AB, Lange, E, Hoffmann, B, Voss, D et al. (2012). Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30: 1210-1216.
32. Diken, M, Kreiter, S, Vascotto, F, Selmi, A, Attig, S, Diekmann, J et al. (2013). mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA. Cancer Immunol Res 1: 386-392.
33. Kreiter, S, Diken, M, Selmi, A, Diekmann, J, Attig, S, Husemann, Y et al. (2011). FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res 71: 6132-6142.
34. Kreiter, S, Selmi, A, Diken, M, Koslowski, M, Britten, CM, Huber, C et al. (2010). Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70: 9031-9040.
35. Schlake, T, Thess, A, Fotin-Mleczek, M and Kallen, KJ (2012). Developing mRNAvaccine technologies. RNA Biol 9: 1319-1330.
36. Pascolo, S (2004). Messenger RNA-based vaccines. Expert Opin Biol Ther 4: 1285-1294.
37. Probst, J, Weide, B, Scheel, B, Pichler, BJ, Hoerr, I, Rammensee, HG et al. (2007). Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acidspecific, saturable and ion dependent. Gene Ther 14: 1175-1180.
38. Kariko, K, Muramatsu, H, Ludwig, J and Weissman, D (2011). Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 39: e142.
39. Cheung, WK, Goon, BL, Guilfoyle, MC and Wacholtz, MC (1998). Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 64: 412-423.
40. McGowan, T, Vaccaro, NM, Beaver, JS, Massarella, J and Wolfson, M (2008). Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 3: 1006-1014.
41. Hope, MJ (2014). Enhancing siRNA delivery by employing lipid nanoparticles. Therapeutic Delivery 5: 663-673.
42. Mays, LE, Ammon-Treiber, S, Mothes, B, Alkhaled, M, Rottenberger, J, Muller-Hermelink, ES et al. (2013). Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism. J Clin Invest 123: 1216-1228.
43. Maier, MA, Jayaraman, M, Matsuda, S, Liu, J, Barros, S, Querbes, W et al. (2013). Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther 21: 1570-1578.
44. Coelho, T, Adams, D, Silva, A, Lozeron, P, Hawkins, PN, Mant, T et al. (2013). Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369: 819-829.
45. Akinc, A, Querbes, W, De, S, Qin, J, Frank-Kamenetsky, M, Jayaprakash, KN et al. (2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18: 1357-1364.